Search the Newsreel

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

Novo Nordisk and AWS bring agentic AI into drug discovery

Novo Nordisk is expanding its collaboration with AWS to integrate agentic AI into its drug discovery processes, including target identification and therapy design. AWS will serve as Novo Nordisk's preferred cloud provider and strategic AI partner, with a co-innovation hub established in London to …

First Trust Advisors LP Lowers Stock Holdings in Novo Nordisk A/S $NVO

Envoy Medical (NASDAQ: COCH) raises cash, advances fully implanted cochlear implant

Envoy Medical (NASDAQ: COCH) reported its Q2 2026 financial results, including a net loss of $7.3 million and net revenue of $51,000. The company significantly increased its cash position to $19.7 million from $3.7 million at year-end 2025, supported by $30 million in equity …

Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

Envoy Medical reported its second quarter 2026 financial results, highlighting significant progress in its corporate initiatives, particularly with its investigational Acclaim® cochlear implant. The company submitted the first module of its modular PMA application to the FDA and announced positive 12-month data from its …

Novo Nordisk Expands Treasury Position as 2026 Share Buyback Nears DKK 8 Billion

Novo Nordisk is actively progressing its share repurchase program for 2026, targeting up to DKK 15 billion. The company has already repurchased 27,884,179 B shares worth DKK 7.78 billion, increasing its treasury stake to 0.9% of its share capital. This move aims to enhance …

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Envoy Medical (NASDAQ:COCH) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Novo Nordisk partners Amazon on London AI hub

Novo Nordisk has partnered with Amazon Web Services (AWS) to establish an AI co-innovation hub in London, aiming to accelerate drug discovery from target identification to human trials. This collaboration makes AWS Novo Nordisk's primary cloud and strategic AI partner, integrating AWS engineers and …

Envoy Medical (NASDAQ: COCH) burns cash on Acclaim implant trial after $28M raise

Envoy Medical (COCH) Announces Q2 2026 Earnings, Files Initial FDA PMA Module, and Reveals Strong Clinical Results for Acclaim® Cochlear Implant

Novo’s Catalent plant ditched in FDA refiling of SMA drug

Scholar Rock has removed Novo Nordisk’s legacy Catalent facility as a contract manufacturer for its spinal muscular atrophy drug, apitegromab, in its FDA refiling due to ongoing issues at the plant. This decision follows multiple FDA citations and an "Official Action Indicated" designation for …

Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution …

Novo Nordisk A/S Q2 Earnings Call Highlights

Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower …

Novo Nordisk makes Omnicom agency of record for US media buying

Novo Nordisk has appointed Omnicom as its agency of record for U.S. media buying, ending its six-year partnership with WPP's Wavemaker. The agreement, valued at $520 million, will see Omnicom manage Novo's media buying in the U.S. starting in the fourth quarter. This move …

FinVolution Group (FINV) Stock News Today

This article provides FinVolution Group (FINV) stock information, including its current trading price, market cap, and P/E ratio. It states that more news regarding the company's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for investors …

FinVolution Group (FINV) Earnings Forecast: Future EPS & Revenue Growth Estimates

FinVolution Group (FINV) has an earnings forecast score of 9.14, ranking 1st in the Financial Technology industry. Analysts provide a strong buy rating, with an average price target of $7.80 and a potential upside of 50.76%. The stock closed at $4.860 with a market …

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Envoy Medical Inc (COCH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lilly and Novo Win a Key GLP-1 Antitrust Fight

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the drugmaker behind Zepbound, won a legal victory alongside Novo Nordisk after a federal judge dismissed an antitrust lawsuit over access to compounded GLP-1 drugs. Warning! GuruFocus has detected 5 Warning Signs …

‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Karsten Munk Knudsen, CFO of Novo Nordisk, described his nine years on the leadership team as a "roller coaster," navigating periods of low growth, hyper-growth fueled by demand for their obesity drugs, and subsequent growth slowdown. He emphasized the pressure and responsibility of steering …

Novo Nordisk Awards U.S. Media Account to Omnicom 08/07/2026

Pharmaceutical giant Novo Nordisk has selected Omnicom as its U.S. media agency of record following a review. The company spends approximately $600 million annually on media and previously worked with WPP's Wavemaker. This new partnership aims to scale consumer-focused strategies and connect with patients, …

Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ...

This article first appeared on GuruFocus. Total Revenue: $0.7 million for Q2 2026, compared to $28.9 million in Q2 2025. Licensing Revenue: Q2 2025 included $27.5 million in licensing revenue from the Novo Nordisk agreement; no comparable revenue was recognized in Q2 2026. R&D …

Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market

A U.S. federal judge has dismissed an antitrust lawsuit against Eli Lilly and Novo Nordisk filed by compounding pharmacy Strive Specialties. Strive had accused the pharmaceutical giants of illegally blocking access to customized versions of their GLP-1 weight-loss drugs through exclusive deals with telehealth …

Novo Nordisk: what the Danish pharma giant does and makes

Novo Nordisk is a Danish pharmaceutical giant founded in 1923, primarily known for its diabetes and obesity treatments, including the blockbuster drugs Ozempic and Wegovy. The company's core business revolves around insulin and GLP-1 receptor agonists like semaglutide, with a significant portion of its …

NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift

Novo Nordisk A/S NVO used its second-quarter 2026 earnings call to emphasize stronger GLP-1 momentum, led by Wegovy pill, while highlighting pricing pressure, patent expirations and competition. The company raised its full-year outlook after adjusted sales and operating profit grew 7% and 11%, respectively, …

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

Novo Nordisk has won a lawsuit in the Netherlands against Ceban Ziekenhuisfarmacie, a compounding pharmacy that was distributing a nasal spray formulation of semaglutide called Semanova. The court ruled that Ceban infringed on Novo Nordisk's supplementary protection certificate (SPC) for semaglutide, which protects Ozempic, …

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

Novo Nordisk, the pharmaceutical giant behind Wegovy, has faced challenges in diversifying its drug portfolio despite its immense success in the weight-loss market. The company recently experienced a setback with its cardiovascular drug ziltivekimab failing phase III trials, causing a 10% drop in its …

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals, Inc. Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET …

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market …

Lilly climbs, Novo falls as obesity drug battle intensifies

Eli Lilly's shares climbed while Novo Nordisk's dropped this week following their respective earnings reports, intensifying the battle for the lucrative GLP-1 obesity and diabetes treatment market. Novo Nordisk faced disappointment with its experimental CagriSema failing to match Lilly's tirzepatide in a trial and …

Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals

Novo Nordisk's CEO, Mike Doustdar, has stated that while the company is open to "bolt-on" acquisitions, it will not pursue large transformative deals despite recent M&A discussions in the pharmaceutical industry. This comes as sales for their Wegovy weight-loss pill continue to surge, with …

Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Wegovy and Ozempic, raised its full-year outlook on Wednesday, but that still wasn't enough to satisfy investors. The stock slid more than 4% in Copenhagen trading as Wall Street looked …

Novo Nordisk Is Exiting a ‘Rough Patch,’ CFO Says. Earnings Prove It.

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes. Continue Reading

Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says

Novo Nordisk's CEO, Maziar Mike Doustdar, stated that the company is not currently in a position to pursue large-scale, transformative mergers and acquisitions, preferring bolt-on acquisitions to complement its internal R&D. This comes as Novo Nordisk faces mixed Q2 results, pipeline setbacks, and aims …